What Is a Blood Bank and How Does It Work?

A blood bank is a facility that collects, tests, processes, stores, and distributes blood and its components for transfusion. Think of it less as a vault where blood sits on shelves and more as a small manufacturing operation with built-in laboratory work: a single donation of whole blood gets broken down into separate products, each one screened for infectious agents, labeled by type, stored under specific conditions, and matched to a patient before it ever reaches a hospital bedside. The chain from a donor’s arm to a patient’s vein involves more steps and more science than most people realize, and each link in that chain exists because something once went wrong.

From Arm to Bag

Blood donation starts with screening the donor. Staff check hemoglobin levels, ask about recent travel, medications, and illnesses, and take vital signs. The hemoglobin cutoff is typically set at 12.5 g/dL to protect both the donor and the quality of the collected unit.¹ A healthy donor loses roughly 200 to 250 milligrams of iron per unit donated, which the body replaces by drawing on ferritin stores. That iron hit is manageable for most people but becomes a real concern for frequent donors, especially women, whose baseline iron stores tend to be smaller.

The most common type of donation is whole blood collection: about 450 milliliters drawn into a bag containing anticoagulant solution. Apheresis is the alternative, where a machine draws blood, separates out a specific component (red cells, platelets, or plasma), and returns the rest to the donor. The cardiovascular and physiological responses to apheresis are modest and comparable to those seen in standard whole blood donation.² Apheresis lets blood banks collect a larger dose of a single component from one donor, which is particularly useful for platelets since a therapeutic dose from whole blood donations requires pooling contributions from multiple people.

Breaking Whole Blood Into Parts

Almost no one receives whole blood anymore. Instead, the blood bank spins the donation in a centrifuge to separate it by weight into packed red blood cells, platelet concentrate, fresh frozen plasma, and sometimes cryoprecipitate.³ This component therapy approach means a single donation can help up to three or four patients, each receiving only the product they need. A trauma patient hemorrhaging on an operating table needs red cells to carry oxygen, a hemophiliac needs clotting factors concentrated in cryoprecipitate, and a burn patient may need plasma to replace lost fluid volume and proteins.

During processing, most blood services also remove white blood cells through a step called leukoreduction. White cells are passengers in the donated blood that offer no benefit to the recipient and can cause problems: fever reactions, immune sensitization, and transmission of viruses that hide inside white cells. Filtering them out reduces febrile transfusion reactions and the risk of alloimmunization, which is when the recipient’s immune system starts making antibodies against donor tissue.⁴ Many countries now mandate universal leukoreduction for all blood products, and the clinical benefits include fewer infections and lower antibiotic use in transfused patients.⁵

Hunting for Infections

Every donated unit undergoes a battery of tests for infectious agents before it can be released. The classic method is serological screening, which looks for antibodies or antigens in the donor’s blood that indicate exposure to viruses like HIV, hepatitis B, and hepatitis C. The problem is that antibodies take time to develop after infection, creating a “window period” when a donor is infected and contagious but tests negative.

That gap is why blood banks added nucleic acid testing, or NAT, which detects the genetic material of viruses directly. NAT catches infections earlier. In one large-scale screening program in India, NAT identified reactive donations at a rate of about 1 in 168 among samples that had already passed serological screening.⁶ A study in Saudi Arabia found 25 donations that were seronegative but NAT-reactive, including cases of hepatitis B, hepatitis C, and HIV.⁷ These are donations that would have reached patients under serological screening alone. NAT does not replace serology; the two are used together as overlapping safety nets.

Bacteria are a separate concern, especially for platelets. Unlike red cells and plasma, platelet concentrates must be stored at room temperature with constant agitation to stay functional, and those warm conditions are ideal for bacterial growth.⁸ Blood services culture platelet units for bacteria before release. Even so, contamination rates are low. A recent Saudi study of over 28,000 platelet components found a culture-confirmed contamination rate of less than 1 per 1,000 units, and the organisms involved were overwhelmingly skin bacteria like Staphylococcus epidermidis, typically introduced during the needle stick itself.⁹ In Germany, safety measures including improved skin disinfection and diversion of the first few milliliters of blood at collection cut pooled platelet contamination rates by about 70% over a roughly eight-year observation period.¹⁰

Matching Blood to Patients

Before a unit of red cells reaches a patient, the blood bank confirms compatibility. The familiar ABO and Rh(D) typing is only the starting point. There are hundreds of known blood group antigens spread across more than 40 systems, and patients who receive many transfusions over time can develop antibodies to antigens they lack. Finding compatible blood for someone who has built up multiple antibodies against common antigens can be genuinely difficult, with some rare phenotypes occurring in fewer than 1 in 1,000 donors.¹¹

Compatibility testing itself has evolved. The traditional method is the antiglobulin crossmatch, where donor red cells and recipient plasma are mixed together and checked for reactions. Many hospitals now use a “type and screen” approach instead: the patient’s blood type is determined and their plasma is screened against a panel of reagent red cells that carry all the clinically important antigens. If no unexpected antibodies are found, units can be released with a simpler immediate-spin crossmatch rather than the full antiglobulin procedure. One prospective study of over 800 patients found perfect agreement between the type-and-screen protocol and the full antiglobulin crossmatch, with no incompatible units slipping through when the antibody screen was negative.¹² The practical payoff is speed: in emergencies, compatible blood gets to the patient faster.

Storage and the Clock

Each blood component has its own storage requirements and shelf life. Red blood cells are refrigerated at 1 to 6°C in additive solutions and can be kept for up to 42 days, depending on the preservative used. Platelets, as mentioned, live at room temperature and expire in just five to seven days, which is partly why platelet shortages are a recurring headache for blood banks. Fresh frozen plasma is frozen at −18°C or colder within hours of collection and can be stored for a year or more.

Red cell storage is not a passive process. From the moment red cells leave the body, they begin accumulating damage. Their normal lifespan in circulation is about 120 days, but the metabolic machinery that keeps them functional depends on conditions that refrigerated storage cannot replicate.¹³ Over weeks in a bag, red cells lose flexibility, shed bits of membrane, leak potassium, and accumulate biochemical changes collectively called the “storage lesion.” Some of the changes that occur during roughly the first two weeks are reversible once the cells re-enter circulation, but changes that accumulate beyond that point become permanent.¹⁴ Whether older stored blood leads to worse patient outcomes compared to fresher blood has been debated for years. Large randomized trials have generally not found a clear clinical difference, but the biology makes clear that fresher is, at a cellular level, better, and blood banks aim to rotate inventory so that the oldest units get used first.

Keeping It Cold on the Move

Maintaining the right temperature from the blood bank refrigerator to the patient’s bedside sounds simple, but it is an underappreciated weak spot. A cross-sectional study that attached temperature monitoring devices to red cell units found that about 10% of temperature readings fell outside the acceptable range during storage and transport combined.¹⁵ The minimum temperature recorded was 0°C and the maximum was 19.5°C, both well outside the 2 to 6°C standard. Most of the out-of-range readings actually occurred within the blood bank itself, not during transport, suggesting that even the home base can have temperature-control lapses.

Validated transport containers help. One validation study confirmed that insulated boxes with appropriate coolant packs maintained blood at 2 to 10°C throughout delivery to both nearby and distant destinations, with the lowest recorded temperature at 3.8°C and the highest at 6.3°C.¹⁶ For remote or field settings, phase-change packs designed for whole blood can hold units between 20 and 24°C for up to 24 hours even under extreme ambient heat.¹⁷ All of this hardware matters because a red cell unit that warms up past the safe zone and then gets re-cooled is not the same product it was before, and blood banks are not allowed to reissue it.

Emergency Protocols and Massive Transfusion

When a patient is hemorrhaging badly enough that they need their entire blood volume replaced, the blood bank activates a massive transfusion protocol. These protocols pre-package coolers of red cells, plasma, and platelets so the clinical team can start transfusing immediately without waiting for type-and-crossmatch results. Current guidelines call for these products to be given in balanced ratios, generally between a 1:1:1 and 1:1:2 ratio of plasma, platelets, and red cells.¹⁸ The rationale is that replacing only red cells without matching amounts of clotting factors and platelets makes bleeding worse, because the patient’s blood becomes diluted and unable to clot.

Timing is critical. Evidence shows that having products physically in the trauma bay when the patient arrives, rather than waiting for a phone call to the blood bank, improves outcomes. In practice, though, there is a tension between readiness and waste. A quality review at one Level 1 trauma center found that about 58% of all blood units issued under massive transfusion protocol were returned unused, and the ratio of what was actually transfused skewed toward more red cells than plasma, not the balanced 1:1:1 that protocols aim for.¹⁹ Returned units that stayed within temperature range can go back into inventory, but those that did not must be discarded. This is a real cost in a system that already struggles with supply.

Managing a Perishable Inventory

Blood products expire. Platelets expire fast. Demand fluctuates unpredictably. These facts make blood bank inventory management more like running a fresh-food distribution network than stocking a warehouse. Order too much and units expire on the shelf. Order too little and patients face delayed or cancelled surgeries.

Forecasting tools help close the gap. One modeling study found that applying time-series forecasting methods to blood product consumption could reduce order frequency by about 60% and inventory levels by roughly 40% while preventing shortages.²⁰ Machine-learning-based platforms have shown similar promise: one integrated system increased collected blood volume by 11% and decreased inventory wastage by 20% compared to the prior year’s figures.²¹ These are still emerging tools, and most blood banks continue to rely on simpler methods supplemented by the experience of their staff, but the direction is clear: data-driven inventory planning is becoming standard infrastructure.

Protecting the Donor

Blood banks depend entirely on voluntary donors, so keeping those donors healthy and willing to return is not just an ethical obligation but a supply-chain necessity. Iron depletion is the most common long-term issue for regular donors. A healthy person donating whole blood loses about 200 to 250 milligrams of iron each time, and the body replenishes that by drawing down ferritin stores. Over repeated donations, ferritin levels drop, and some donors eventually become iron-deficient or anemic enough to be deferred at their next visit.¹

A Cochrane systematic review found that giving donors iron supplements cut the rate of deferral for low hemoglobin by roughly two-thirds at the next donation visit, with even larger effects at later visits. Supplemented donors also had measurably higher hemoglobin and ferritin levels.²² Despite this evidence, routine iron supplementation for donors is still not universal practice. Some blood services hand out iron tablets, others simply extend the minimum interval between donations, and many do neither systematically. Research continues to push for better iron-status monitoring and targeted supplementation to keep donors in the system safely.²³

Pathogen Reduction Technology

Traditional blood safety relies on testing: find infections and throw out the positive units. Pathogen reduction flips the approach. Instead of looking for specific bugs, it treats the blood product to inactivate whatever might be in there, whether you know about it or not. Four major platforms are in use or late-stage development, all working on the same principle: a photosensitive chemical is added to the blood product, and UV light is applied. The light activates the chemical, which damages the nucleic acids of any viruses, bacteria, or parasites present, preventing them from replicating.²⁴

One of these systems uses riboflavin (vitamin B2) combined with UV light. It gained particular attention during the COVID-19 pandemic when researchers demonstrated that it could reduce SARS-CoV-2 in plasma by more than 4.7 log units and in whole blood by over 3.3 log units, effectively rendering the virus undetectable in treated plasma.²⁵ The appeal of pathogen reduction is that it provides a defense against threats that testing cannot yet detect, including novel or emerging pathogens for which no screening assay exists. The tradeoff is cost and some degree of damage to the blood product itself, since the treatment is not perfectly selective.

Patient Blood Management

A growing philosophy in transfusion medicine treats blood bank products as a resource to be minimized, not maximized. Patient blood management focuses on reducing the need for transfusion in the first place: correcting a patient’s anemia before elective surgery, using drugs that reduce surgical bleeding, and salvaging the patient’s own blood during operations for reinfusion. One coronary artery bypass study described a comprehensive protocol that included preoperative iron supplementation, erythropoietin when needed, antifibrinolytic drugs during surgery, and intraoperative cell salvage alongside a more restrictive transfusion threshold.²⁶

Intraoperative blood recovery, where blood lost during surgery is collected, washed, and returned to the patient, has become a standard component of these programs. Guidelines from major health authorities, including the World Health Organization, now advocate broader implementation of cell salvage in surgeries with significant bleeding risk.²⁷ The benefit goes both ways: patients face fewer transfusion-related complications, and blood banks face less pressure on a finite supply.

Lab-Grown Red Blood Cells

The ultimate solution to blood supply problems would be manufacturing red cells in a lab. Researchers have been working on growing red blood cells from stem cells for years, and the science has reached the point where functional, enucleated red cells (meaning they have shed their nucleus, like mature red cells in your body) can be produced in culture. The challenge is scale and efficiency. Recent work has focused on optimizing the culture medium, particularly cholesterol levels, to improve how many usable cells survive the final purification step. Adding cholesterol at a specific stage of cell maturation increased the mechanical toughness of the lab-grown cells and improved the yield of purified red cells after filtration.²⁸

Separately, researchers have developed a chemically defined culture system that can generate lab-grown red cells from multiple types of starting material without needing human plasma or serum, which would simplify manufacturing and reduce costs.²⁹ A small clinical trial in the UK has already transfused lab-grown red cells into human volunteers. But producing the trillions of cells needed for a single standard transfusion unit remains orders of magnitude beyond current capacity. Lab-grown blood is not going to replace donors anytime soon, but for patients with extremely rare blood types who depend on a handful of compatible donors worldwide, even small-scale production could be transformative.